Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.

Authors

Jhanelle Elaine Gray

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Jhanelle Elaine Gray , Taofeek Kunle Owonikoko , Terufumi Kato , Andres Felipe Cardona Zorrilla , Joanne Wagman , Xinqun Chen , Bin Zhao , Christian Schulz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.

First Author: Marina Chiara Garassino

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.

First Author: Martin Reck

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non–small cell lung carcinoma (NSCLC): KEYNOTE-189.

First Author: Richard Delmar Hall

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.

First Author: Helena Alexandra Yu